Arrowhead Pharmaceuticals announced the presentation of new preclinical data on its expanding pipeline of RNA interference therapeutics for cardiometabolic diseases, including ARO-ANG3, which targets angiopoietin-like protein 3
, and ARO-APOC3, which targets apolipoprotein C-III.
Other medications belonging to the classes of antisense oligonucleotides are those that inhibit the production of the angiopoietin-like protein 3
The product is an investigational monoclonal antibody to angiopoietin-like protein 3
Mabuchi et al., "Association of angiopoietin-like protein 3
with hepatic triglyceride lipase and lipoprotein lipase activities in human plasma," Annals of Clinical Biochemistry, vol.
Maranghi, "The angiopoietin-like protein 3
: a hepatokine with expanding role in metabolism," Current Opinion in Lipidology, vol.